Free Trial

Century Therapeutics (IPSC) News Today

$2.97
-0.03 (-1.00%)
(As of 05/21/2024 ET)
Century Therapeutics, Inc. (NASDAQ:IPSC) Sees Large Decline in Short Interest
Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) was the recipient of a large drop in short interest in the month of April. As of April 30th, there was short interest totalling 1,560,000 shares, a drop of 9.8% from the April 15th total of 1,730,000 shares. Approximately 5.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 194,700 shares, the short-interest ratio is currently 8.0 days.
HC Wainwright Lowers Century Therapeutics (NASDAQ:IPSC) Price Target to $11.00
HC Wainwright dropped their target price on shares of Century Therapeutics from $13.00 to $11.00 and set a "buy" rating on the stock in a report on Friday.
Insider Selling: Century Therapeutics, Inc. (NASDAQ:IPSC) Insider Sells 5,000 Shares of Stock
Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) insider Gregory Russotti sold 5,000 shares of Century Therapeutics stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $3.12, for a total value of $15,600.00. Following the sale, the insider now owns 292,319 shares of the company's stock, valued at approximately $912,035.28. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Century Therapeutics' (IPSC) "Overweight" Rating Reaffirmed at Piper Sandler
Piper Sandler reiterated an "overweight" rating and issued a $9.00 target price (down previously from $10.00) on shares of Century Therapeutics in a report on Friday.
Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Update
Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) was the recipient of a significant decline in short interest in March. As of March 15th, there was short interest totalling 1,640,000 shares, a decline of 6.3% from the February 29th total of 1,750,000 shares. Based on an average daily trading volume, of 214,300 shares, the short-interest ratio is presently 7.7 days. Approximately 7.6% of the company's shares are sold short.
Canaccord Genuity Group Increases Century Therapeutics (NASDAQ:IPSC) Price Target to $24.00
Canaccord Genuity Group lifted their price objective on Century Therapeutics from $22.00 to $24.00 and gave the company a "buy" rating in a report on Friday.
Century Therapeutics (NASDAQ:IPSC) Receives Buy Rating from HC Wainwright
HC Wainwright restated a "buy" rating and set a $13.00 price target on shares of Century Therapeutics in a report on Friday.
Century Therapeutics, Inc. (NASDAQ:IPSC) Receives Average Recommendation of "Moderate Buy" from Brokerages
Shares of Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) have received an average recommendation of "Moderate Buy" from the six research firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have give
Century Therapeutics: Q4 Earnings Insights
Century Therapeutics, Inc. (NASDAQ:IPSC) Insider Adrienne Farid Sells 22,831 Shares
Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) insider Adrienne Farid sold 22,831 shares of the stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $5.14, for a total transaction of $117,351.34. Following the transaction, the insider now directly owns 114,149 shares in the company, valued at approximately $586,725.86. The transaction was disclosed in a filing with the SEC, which is available through this link.
Fmr LLC Cuts Holdings in Century Therapeutics, Inc. (NASDAQ:IPSC)
Fmr LLC trimmed its holdings in shares of Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report) by 12.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 4,524,629 shares of the company's stock after selling 643,
Short Interest in Century Therapeutics, Inc. (NASDAQ:IPSC) Increases By 6.4%
Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 846,300 shares, a growth of 6.4% from the January 15th total of 795,600 shares. Currently, 3.7% of the company's shares are sold short. Based on an average daily volume of 183,100 shares, the days-to-cover ratio is currently 4.6 days.
IPSC Century Therapeutics, Inc.
Century Therapeutics Inc (IPSC)
Get Century Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IPSC and its competitors with MarketBeat's FREE daily newsletter.

This military-backed stock “owns” AI market (Ad)

The AI boom is just getting started. And the real wealth has still to be made…

You must read this new presentation from Porter Stansberry.

IPSC Media Mentions By Week

IPSC Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

IPSC
News Sentiment

1.06

0.43

Average
Medical
News Sentiment

IPSC News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

IPSC Articles
This Week

3

1

IPSC Articles
Average Week

Get Century Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IPSC and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:IPSC) was last updated on 5/22/2024 by MarketBeat.com Staff

From Our Partners